(Q48119124)

8 February 2018

title

The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. (English)

1 reference

8 February 2018

0 references

1 reference

4

1 reference

8 February 2018

author name string

Broussolle E

1

1 reference

8 February 2018

Dentresangle C

2

1 reference

8 February 2018

Landais P

3

1 reference

8 February 2018

Pollak P

5

1 reference

8 February 2018

Croisile B

6

1 reference

8 February 2018

Hibert O

7

1 reference

8 February 2018

Bonnefoi F

8

1 reference

8 February 2018

Galy G

9

1 reference

8 February 2018

Froment JC

10

1 reference

8 February 2018

Comar D

11

1 reference

8 February 2018

publication date

1 July 1999

1 reference

8 February 2018

Journal of the Neurological Sciences

published in

1 reference

8 February 2018

volume

166

1 reference

8 February 2018

issue

2

1 reference

8 February 2018

page(s)

141-151

1 reference

8 February 2018

Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Cognitive function in Parkinson's disease: From description to theory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Cognitive deficits in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Age-induced cognitive disturbances in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Depression in Parkinson's disease: a quantitative and qualitative analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Cognitive deficits in the early stages of Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Cognitive impairments associated with early Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Fronto-striatal cognitive deficits at different stages of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Functional architecture of basal ganglia circuits: neural substrates of parallel processing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Intellectual changes in patients with MPTP-induced parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Neuropsychological performance in lateralized parkinsonism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Side of onset of motor symptoms influences cognition in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Brain responses to detection of right or left somatic targets are symmetrical in unilateral Parkinson's disease: a case against the concept of "parkinsonian neglect'.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

P3 latency change in aging and Parkinson disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Motor and cognitive performances of parkinsonian patients in the on and off phases of the disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Impaired simultaneous cognitive task performance in Parkinson's disease: a dopamine-related dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15-objects test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Dopaminergic induced changes in cognitive and motor processing in Parkinson's disease: an electrophysiological investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Cognition and the basal ganglia. Separating mental and motor components of performance in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

P300 variations in parkinsonian patients before and during dopaminergic monotherapy: a suggested dopamine component in P300.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Cholinergic deficiency and frontal dysfunction in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Functional effects of striatal dysfunction in Parkinson disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Registration of dynamic dopamine D2 receptor images using principal component analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Factor analysis and the cerebral hemispheres: "unlocalized" functions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

EP component identification and measurement by principal components analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

The metabolic topography of parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Core assessment program for intracerebral transplantations (CAPIT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Presenile dementia. Clinical aspects and evaluation of cerebrospinal fluid dynamics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Learning deficit in Parkinson's disease. Comparison with Alzheimer's disease and normal aging.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

The Mattis Dementia Rating Scale: normative data from 1,001 healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Screening for dementia by memory testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Augmenting mental chronometry: the P300 as a measure of stimulus evaluation time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

On the dependence of P300 latency on stimulus evaluation processes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Unmasking of cortical SEP components by changes in stimulus rate: a topographic study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Clinical observations on the rate of progression of idiopathic parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Clinical and [18F] dopa PET findings in early Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Cognition in Parkinson disease: an event-related potential perspective.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Modality dependent changes in event-related potentials correlate with specific cognitive functions in nondemented patients with Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900127-6

10.1016/S0022-510X(99)00127-6

7 January 2021

Identifiers

DOI

1 reference

8 February 2018

PubMed ID

10475108

1 reference

8 February 2018